{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:31:00Z","timestamp":1781796660984,"version":"3.54.5"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13555-025-01462-7","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T13:31:26Z","timestamp":1751203886000},"page":"2317-2333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Falk G.","family":"Bechara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessel H.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Jordan M.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Alarcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel P.","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,29]]},"reference":[{"issue":"4","key":"1462_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1462_CR2","unstructured":"Ballard K, Shuman VL. Hidradenitis suppurativa. 2024 May 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan\u2013. PMID: 30521288. StatPearls2024."},{"issue":"6","key":"1462_CR3","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/bjd.16603","volume":"183","author":"L Matusiak","year":"2020","unstructured":"Matusiak L. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1462_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13555-023-01085-w","volume":"14","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Kirby J, Ingram JR, et al. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatol Ther (Heidelb). 2024;14(1):83\u201398.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1462_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1468-3083.2012.04468.x","volume":"27","author":"AJ Onderdijk","year":"2013","unstructured":"Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27(4):473\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1462_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","volume":"155","author":"MO Machado","year":"2019","unstructured":"Machado MO, Stergiopoulos V, Maes M, et al. Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(8):939\u201345.","journal-title":"JAMA Dermatol"},{"issue":"13","key":"1462_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.21037\/atm-20-1028","volume":"8","author":"K Phan","year":"2020","unstructured":"Phan K, Huo YR, Smith SD. Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis. Ann Transl Med. 2020;8(13):821.","journal-title":"Ann Transl Med"},{"issue":"2","key":"1462_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bjd\/ljad345","volume":"190","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Frew J, Jemec GBE, et al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol. 2024;190(2):149\u201362.","journal-title":"Br J Dermatol"},{"issue":"13","key":"1462_CR9","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.3390\/ijerph18136709","volume":"18","author":"T Montero-Vilchez","year":"2021","unstructured":"Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo JA, et al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18(13):6709","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"1462_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1462_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijwd.2019.06.026","volume":"5","author":"A Cartron","year":"2019","unstructured":"Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol. 2019;5(5):330\u20134.","journal-title":"Int J Womens Dermatol"},{"issue":"1","key":"1462_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/derm.2.1.12490","volume":"2","author":"S Fimmel","year":"2010","unstructured":"Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2(1):9\u201316.","journal-title":"Dermatoendocrinol"},{"issue":"1","key":"1462_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13555-020-00354-2","volume":"10","author":"T Tzellos","year":"2020","unstructured":"Tzellos T, Zouboulis CC. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther (Heidelb). 2020;10(1):63\u201371.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1462_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjd.21293","volume":"186","author":"N Kearney","year":"2022","unstructured":"Kearney N, Kirby B. The prevalence of hidradenitis suppurativa outside the hospital setting: the impact of the undiagnosed. Br J Dermatol. 2022;186(5):767\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1462_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1462_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","volume":"157","author":"A Jfri","year":"2021","unstructured":"Jfri A, Nassim D, O\u2019Brien E, et al. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021;157(8):924\u201331.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1462_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/der2.113","volume":"3","author":"EK Kozera","year":"2022","unstructured":"Kozera EK, Frew JW. The pathogenesis of hidradenitis suppurativa: evolving paradigms in a complex disease. Dermatol Rev. 2022;3(2):39\u201349.","journal-title":"Dermatol Rev"},{"issue":"12","key":"1462_CR18","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.14214","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa? 15 years after. Exp Dermatol. 2020;29(12):1154\u201370.","journal-title":"Exp Dermatol"},{"issue":"2","key":"1462_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000517017","volume":"238","author":"KP Kaleta","year":"2022","unstructured":"Kaleta KP, Nikolakis G, Hossini AM, et al. Metabolic disorders\/obesity is a primary risk factor in hidradenitis suppurativa: an immunohistochemical real-world approach. Dermatology. 2022;238(2):251\u20139.","journal-title":"Dermatology"},{"issue":"5","key":"1462_CR20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045\u201358.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1462_CR21","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/biomedicines10082039","volume":"10","author":"C Moltrasio","year":"2020","unstructured":"Moltrasio C, Tricarico PM, Romagnuolo M, Marzano AV, Crovella S. Hidradenitis suppurativa: a perspective on genetic factors involved in the disease. Biomedicines. 2022;10(8):2039","journal-title":"Biomedicines"},{"issue":"5","key":"1462_CR22","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1159\/000521263","volume":"238","author":"AV Marzano","year":"2022","unstructured":"Marzano AV, Genovese G, Moltrasio C, et al. Whole-exome sequencing in 10 unrelated patients with syndromic hidradenitis suppurativa: a preliminary step for a genotype-phenotype correlation. Dermatology. 2022;238(5):860\u20139.","journal-title":"Dermatology"},{"issue":"4","key":"1462_CR23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/jdv.16147","volume":"34","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Nogueira da Costa A, Makrantonaki E, et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34(4):846\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1462_CR24","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jdv.18163","volume":"36","author":"JR Ingram","year":"2022","unstructured":"Ingram JR, Bettoli V, Espy JI, et al. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. J Eur Acad Dermatol Venereol. 2022;36(9):1597\u2013605.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1462_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project. J Am Acad Dermatol. 2020;82(2):366\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1462_CR26","doi-asserted-by":"publisher","first-page":"e592","DOI":"10.1111\/ajd.13672","volume":"62","author":"JW Rick","year":"2021","unstructured":"Rick JW, Thompson AM, Fernandez JM, et al. Misdiagnoses and barriers to care in hidradenitis suppurativa: a patient survey. Australas J Dermatol. 2021;62(4):e592\u20134.","journal-title":"Australas J Dermatol"},{"issue":"6","key":"1462_CR27","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1462_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000534845","volume":"10","author":"I Aparicio Martins","year":"2024","unstructured":"Aparicio Martins I, Figueira Vilela B, Cabete J. Diagnostic delay in hidradenitis suppurativa: still an unsolved problem. Skin Appendage Disord. 2024;10(2):129\u201332.","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"1462_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000529194","volume":"239","author":"A Bilgic","year":"2023","unstructured":"Bilgic A, Fettahlioglu Karaman B, Demirseren DD, et al. Internalized stigma in hidradenitis suppurativa: a multicenter cross-sectional study. Dermatology. 2023;239(3):445\u201353.","journal-title":"Dermatology"},{"issue":"2","key":"1462_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Del Marmol V, Mrowietz U, et al. Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231(2):184\u201390.","journal-title":"Dermatology"},{"issue":"6","key":"1462_CR31","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/bjd.17927","volume":"181","author":"F Benhadou","year":"2019","unstructured":"Benhadou F, Van der Zee HH, Pascual JC, et al. Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa\/acne inversa: a cross-sectional study among 2465 patients. Br J Dermatol. 2019;181(6):1198\u2013206.","journal-title":"Br J Dermatol"},{"key":"1462_CR32","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2147\/CCID.S301794","volume":"16","author":"CL Snyder","year":"2023","unstructured":"Snyder CL, Chen SX, Porter ML. Obstacles to early diagnosis and treatment of hidradenitis suppurativa: current perspectives on improving clinical management. Clin Cosmet Investig Dermatol. 2023;16:1833\u201341.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"1462_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5021\/ad.23.090","volume":"36","author":"Y Kim","year":"2024","unstructured":"Kim Y, Lee J, Kim HS, et al. Review of scoring systems for hidradenitis suppurativa. Ann Dermatol. 2024;36(1):9\u201317.","journal-title":"Ann Dermatol"},{"key":"1462_CR34","doi-asserted-by":"publisher","first-page":"1145152","DOI":"10.3389\/fmed.2023.1145152","volume":"10","author":"M Daoud","year":"2023","unstructured":"Daoud M, Suppa M, Benhadou F, et al. Overview and comparison of the clinical scores in hidradenitis suppurativa: a real-life clinical data. Front Med (Lausanne). 2023;10:1145152.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1462_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.clindermatol.2023.08.016","volume":"41","author":"NDK Koerts","year":"2023","unstructured":"Koerts NDK, Bouwman K, Prens LM, Horvath B. Assessment tools and phenotype classification for hidradenitis suppurativa. Clin Dermatol. 2023;41(5):601\u201310.","journal-title":"Clin Dermatol"},{"key":"1462_CR36","doi-asserted-by":"crossref","unstructured":"van Straalen KR, Ingram JR, Augustin M, Zouboulis CC. New treatments and new assessment instruments for Hidradenitis suppurativa. Exp Dermatol. 2022;31 Suppl 1(Suppl 1):33\u20139.","DOI":"10.1111\/exd.14609"},{"issue":"Suppl 1","key":"1462_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/exd.14123","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Gulliver W, Ingram J, et al. Endpoints of clinical trials for hidradenitis suppurativa: proceedings of a round-table session. Exp Dermatol. 2020;29(Suppl 1):67\u201372.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1462_CR38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2340\/00015555-2513","volume":"97","author":"B Horvath","year":"2017","unstructured":"Horvath B, Janse IC, Blok JL, et al. Hurley staging refined: a proposal by the dutch hidradenitis suppurativa expert group. Acta Derm Venereol. 2017;97(3):412\u20133.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1462_CR39","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434\u201342.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1462_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","volume":"37","author":"T Tzellos","year":"2023","unstructured":"Tzellos T, van Straalen KR, Kyrgidis A, et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37(2):395\u2013401.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1462_CR41","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000528968","volume":"239","author":"KR van Straalen","year":"2023","unstructured":"van Straalen KR, Tzellos T, Alavi A, et al. External validation of the IHS4-55 in a European antibiotic-treated hidradenitis suppurativa cohort. Dermatology. 2023;239(3):362\u20137.","journal-title":"Dermatology"},{"issue":"5","key":"1462_CR42","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1462_CR43","first-page":"868","volume":"22","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, Bechara FG, Fritz K, et al. S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa\u2014Short version. J Dtsch Dermatol Ges. 2024;22(6):868\u201389.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"1462_CR44","first-page":"765","volume":"5","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2024;5(5):765\u201378","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1462_CR45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamadermatol.2017.5890","volume":"154","author":"S Hessam","year":"2018","unstructured":"Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa. JAMA Dermatol. 2018;154(3):330\u20135.","journal-title":"JAMA Dermatol"},{"key":"1462_CR46","doi-asserted-by":"crossref","unstructured":"Zouboulis C, Bechara F, Fritz K, et al. S2k-Leitlinie zur Therapie der Hidradenitis suppurativa\/Acne inversa (ICD-10-Code: L73.2). Aktuelle Dermatologie. 2024;50:30\u201383.","DOI":"10.1055\/a-2225-7983"},{"issue":"2","key":"1462_CR47","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.18692","volume":"183","author":"JS Kirby","year":"2020","unstructured":"Kirby JS, Thorlacius L, Villumsen B, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. 2020;183(2):340\u20138.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1462_CR48","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179(3):642\u201350.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1462_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijwd.2019.11.004","volume":"6","author":"E Nesbitt","year":"2020","unstructured":"Nesbitt E, Clements S, Driscoll M. A concise clinician\u2019s guide to therapy for hidradenitis suppurativa. Int J Womens Dermatol. 2020;6(2):80\u20134.","journal-title":"Int J Womens Dermatol"},{"issue":"1","key":"1462_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000503605","volume":"237","author":"AJ Hendricks","year":"2021","unstructured":"Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology. 2021;237(1):81\u201396.","journal-title":"Dermatology"},{"issue":"2","key":"1462_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","volume":"85","author":"KR van Straalen","year":"2021","unstructured":"van Straalen KR, Tzellos T, Guillem P, et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study. J Am Acad Dermatol. 2021;85(2):369\u201378.","journal-title":"J Am Acad Dermatol"},{"key":"1462_CR52","unstructured":"European Medicines Agency. Humira summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf [Internet]. Accessed 19 June 2025."},{"key":"1462_CR53","unstructured":"US Food and Drug Administration. Humira Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125057s423lbl.pdf#page=57. Accessed 19 June 2025."},{"issue":"5","key":"1462_CR54","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"1462_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60\u20139 e2.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1462_CR56","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/jdv.17598","volume":"35","author":"W Gulliver","year":"2021","unstructured":"Gulliver W, Alavi A, Wiseman MC, et al. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol. 2021;35(12):2431\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1462_CR57","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.17551","volume":"35","author":"A Hafner","year":"2021","unstructured":"Hafner A, Ghislain PD, Kovacs R, et al. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: real-world results from the HARMONY study. J Eur Acad Dermatol Venereol. 2021;35(11):2277\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1462_CR58","unstructured":"European Medicines Agency. Cosentyx summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf. Last Accessed Mar 2024."},{"key":"1462_CR59","unstructured":"US Food and Drug Administration. Cosentyx prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125504s066,761349s004lbl.pdf. Last Accessed Mar 2024."},{"issue":"10378","key":"1462_CR60","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361.","journal-title":"Lancet"},{"key":"1462_CR61","unstructured":"UCB press release. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-receives-European-Commission-approval-for-BIMZELXRVbimekizumab-as-the-first-IL-17A-and-IL-17F-biologic-for-moderate-to-severe-hidradenitis-suppurativa. Accessed 30 May 2024 [press release]."},{"key":"1462_CR62","unstructured":"European Medicines Agency. Bimzelx summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf. Accessed 19 June 2025."},{"issue":"10443","key":"1462_CR63","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504\u201319.","journal-title":"Lancet"},{"key":"1462_CR64","unstructured":"Bimzelx Prescribing information. https:\/\/www.ucb-usa.com\/bimzelx-prescribing-information.pdf. Accessed 07 Dec 2024."},{"issue":"5","key":"1462_CR65","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40257-024-00880-1","volume":"25","author":"JL Gao","year":"2024","unstructured":"Gao JL, Otto TS, Porter ML, Kimball AB. Hidradenitis suppurativa: new targets and emerging treatments. Am J Clin Dermatol. 2024;25(5):765\u201378.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1462_CR66","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/jdv.19810","volume":"38","author":"PK Krajewski","year":"2024","unstructured":"Krajewski PK, Sanz-Motilva V, Flores Martinez S, et al. Deroofing: a safe, effective and well-tolerated procedure in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2024;38(5):931\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1462_CR67","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1462_CR68","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/1203475417716117","volume":"21","author":"A Alavi","year":"2017","unstructured":"Alavi A, Lynde C, Alhusayen R, et al. Approach to the management of patients with hidradenitis suppurativa: a consensus document. J Cutan Med Surg. 2017;21(6):513\u201324.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"1462_CR69","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2020.09.039","volume":"85","author":"KT Savage","year":"2021","unstructured":"Savage KT, Singh V, Patel ZS, et al. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. J Am Acad Dermatol. 2021;85(1):187\u201399.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1462_CR70","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421\u201330.","journal-title":"Dermatology"},{"issue":"Suppl 6","key":"1462_CR71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/jdv.15850","volume":"33","author":"A Chiricozzi","year":"2019","unstructured":"Chiricozzi A, Micali G, Veraldi S. The patient journey: a voyage from diagnosis to hidradenitis suppurativa multidisciplinary unit. J Eur Acad Dermatol Venereol. 2019;33(Suppl 6):15\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1462_CR72","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ced.14826","volume":"47","author":"N Kashetsky","year":"2022","unstructured":"Kashetsky N, Mukovozov IM, Pereira J, et al. Patient experiences with hidradenitis suppurativa: the Hidradenitis Patient Experience survey. Clin Exp Dermatol. 2022;47(1):72\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1462_CR73","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bjd.17716","volume":"181","author":"L Thorlacius","year":"2019","unstructured":"Thorlacius L, Garg A, Riis PT, et al. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. Br J Dermatol. 2019;181(3):483\u201391.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1462_CR74","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/bjd.19798","volume":"184","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC. Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br J Dermatol. 2021;184(6):1203\u20134.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1462_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, et al. Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133\u201340.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1462_CR76","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ad.2022.12.005","volume":"115","author":"FJ Melgosa Ramos","year":"2024","unstructured":"Melgosa Ramos FJ, Garcia-Ruiz R, Mateu Puchades A, Martorell A. Can we improve prognosis in hidradenitis suppurativa? Identifying patients in the window of opportunity. Actas Dermosifiliogr. 2024;115(2):213\u20134.","journal-title":"Actas Dermosifiliogr"},{"issue":"Suppl 2","key":"1462_CR77","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0001-7310(17)30007-8","volume":"107","author":"A Martorell","year":"2016","unstructured":"Martorell A, Caballero A, Gonzalez Lama Y, et al. Management of patients with hidradenitis suppurativa. Actas Dermosifiliogr. 2016;107(Suppl 2):32\u201342.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"1462_CR78","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jid.2020.08.032","volume":"141","author":"S Cazzaniga","year":"2021","unstructured":"Cazzaniga S, Pezzolo E, Bettoli V, et al. Characterization of hidradenitis suppurativa phenotypes: a multidimensional latent class analysis of the National Italian Registry IRHIS. J Investig Dermatol. 2021;141(5):1236\u201342 e1.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"1462_CR79","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/jid.2012.472","volume":"133","author":"F Canoui-Poitrine","year":"2013","unstructured":"Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Investig Dermatol. 2013;133(6):1506\u201311.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"1462_CR80","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/bjd.17695","volume":"181","author":"JW Frew","year":"2019","unstructured":"Frew JW, Hawkes JE, Sullivan-Whalen M, Gilleaudeau P, Krueger JG. Inter-rater reliability of phenotypes and exploratory genotype-phenotype analysis in inherited hidradenitis suppurativa. Br J Dermatol. 2019;181(3):566\u201371.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1462_CR81","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jaad.2018.02.048","volume":"79","author":"KR van Straalen","year":"2018","unstructured":"van Straalen KR, Verhagen T, Horvath B, et al. Poor interrater reliability of hidradenitis suppurativa phenotypes. J Am Acad Dermatol. 2018;79(3):577\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1462_CR82","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jid.2020.10.014","volume":"141","author":"JS Kirby","year":"2021","unstructured":"Kirby JS. Unraveling the heterogeneity of hidradenitis suppurativa with phenotype schema. J Investig Dermatol. 2021;141(5):1136\u20138.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"1462_CR83","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/jid.2012.476","volume":"133","author":"JR Ingram","year":"2013","unstructured":"Ingram JR, Piguet V. Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step toward personalized therapy. J Investig Dermatol. 2013;133(6):1453\u20136.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1462_CR84","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/jdv.19481","volume":"38","author":"MA Visan","year":"2024","unstructured":"Visan MA, Caruntu C, Costache RS, Tiplica G, Costache DO. Hidradenitis suppurativa: detangling phenotypes and identifying common denominators. J Eur Acad Dermatol Venereol. 2024;38(1):62\u201376.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1462_CR85","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaad.2014.04.001","volume":"71","author":"AM Schrader","year":"2014","unstructured":"Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71(3):460\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1462_CR86","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/ced.14478","volume":"46","author":"E Ozkur","year":"2021","unstructured":"Ozkur E, Karadag AS, Ustuner P, et al. Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity. Clin Exp Dermatol. 2021;46(3):532\u201340.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"1462_CR87","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.3390\/jcm12123921","volume":"12","author":"A Hammud","year":"2023","unstructured":"Hammud A, Avitan-Hersh E, Khamaysi Z. Clinical-epidemiological characteristics of hidradenitis suppurativa: a retrospective cohort study from a tertiary care centre in Northern Israel. J Clin Med. 2023;12(12):3921","journal-title":"J Clin Med"},{"issue":"5\u20136","key":"1462_CR88","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000491547","volume":"234","author":"A Vanlaerhoven","year":"2018","unstructured":"Vanlaerhoven A, Ardon CB, van Straalen KR, et al. Hurley III hidradenitis suppurativa has an aggressive disease course. Dermatology. 2018;234(5\u20136):232\u20133.","journal-title":"Dermatology"},{"issue":"3","key":"1462_CR89","first-page":"240","volume":"157","author":"RD Caposiena Caro","year":"2022","unstructured":"Caposiena Caro RD, Chiricozzi A, Sechi A, et al. Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data. Ital J Dermatol Venerol. 2022;157(3):240\u20136.","journal-title":"Ital J Dermatol Venerol"},{"issue":"2","key":"1462_CR90","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14829","volume":"34","author":"M Sanchez-Diaz","year":"2021","unstructured":"Sanchez-Diaz M, Martinez-Lopez A, Salvador-Rodriguez L, et al. The role of biologic treatment in special scenarios in hidradenitis suppurativa: facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema. Dermatol Ther. 2021;34(2): e14829.","journal-title":"Dermatol Ther"},{"issue":"11","key":"1462_CR91","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.annder.2017.03.026","volume":"144","author":"J Revuz","year":"2017","unstructured":"Revuz J. Disseminate recurrent folliculitis as the presenting picture of hidradenitis suppurativa. Ann Dermatol Venereol. 2017;144(11):715\u20138.","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"1462_CR92","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/jdv.16183","volume":"34","author":"A Martorell","year":"2020","unstructured":"Martorell A, Jfri A, Koster SBL, et al. Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1309\u201318.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1462_CR93","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/bjd\/ljad028","volume":"188","author":"P Mendes-Bastos","year":"2023","unstructured":"Mendes-Bastos P, Martorell A, Bettoli V, et al. The use of ultrasound and magnetic resonance imaging in the management of hidradenitis suppurativa: a narrative review. Br J Dermatol. 2023;188(5):591\u2013600.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1462_CR94","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jaad.2022.08.064","volume":"88","author":"PK Krajewski","year":"2023","unstructured":"Krajewski PK, Jfri A, Ochando-Ibernon G, Martorell A. Ultrasonographic railway sign in tunnels as a new independent risk factor of adalimumab failure in hidradenitis suppurativa. J Am Acad Dermatol. 2023;88(3):732\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1462_CR95","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/DSS.0000000000001916","volume":"45","author":"A Martorell","year":"2019","unstructured":"Martorell A, Giovanardi G, Gomez-Palencia P, Sanz-Motilva V. Defining fistular patterns in hidradenitis suppurativa: impact on the management. Dermatol Surg. 2019;45(10):1237\u201344.","journal-title":"Dermatol Surg"},{"issue":"11","key":"1462_CR96","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/jdv.15710","volume":"33","author":"A Martorell","year":"2019","unstructured":"Martorell A, Alfageme Roldan F, Vilarrasa Rull E, et al. Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study. J Eur Acad Dermatol Venereol. 2019;33(11):2137\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1462_CR97","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000495982","volume":"235","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Nogueira da Costa A, Jemec GBE, Trebing D. Long-wave medical infrared thermography: a clinical biomarker of inflammation in hidradenitis suppurativa\/acne inversa. Dermatology. 2019;235(2):144\u20139.","journal-title":"Dermatology"},{"issue":"5","key":"1462_CR98","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20(5):525\u201345.","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 1","key":"1462_CR99","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/exd.14338","volume":"30","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021;30(Suppl 1):8\u201317.","journal-title":"Exp Dermatol"},{"issue":"11","key":"1462_CR100","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","volume":"156","author":"FG Bechara","year":"2021","unstructured":"Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001\u20139.","journal-title":"JAMA Surg"},{"issue":"10281","key":"1462_CR101","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301\u201315.","journal-title":"Lancet"},{"issue":"4","key":"1462_CR102","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1159\/000514535","volume":"237","author":"S Zhou","year":"2021","unstructured":"Zhou S, Qi F, Gong Y, Zhang J, Zhu B. Biological therapies for atopic dermatitis: a systematic review. Dermatology. 2021;237(4):542\u201352.","journal-title":"Dermatology"},{"key":"1462_CR103","doi-asserted-by":"crossref","unstructured":"McMullen E, Metko D, Mehta S, et al. Machine learning applications in hidradenitis suppurativa diagnosis, management, and severity assessment: a systematic review. J Cutan Med Surg. 2024:12034754241303091.","DOI":"10.1177\/12034754241303091"},{"issue":"4","key":"1462_CR104","first-page":"516","volume":"14","author":"F Li Pomi","year":"2024","unstructured":"Li Pomi F, Papa V, Borgia F, et al. Artificial intelligence: a snapshot of its application in chronic inflammatory and autoimmune skin diseases. Life (Basel). 2024;14(4):516","journal-title":"Life (Basel)"},{"key":"1462_CR105","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.2147\/CCID.S478309","volume":"17","author":"AC Ezanno","year":"2024","unstructured":"Ezanno AC, Fougerousse AC, Pruvost-Balland C, et al. AI in hidradenitis suppurativa: expert evaluation of patient-facing information. Clin Cosmet Investig Dermatol. 2024;17:2459\u201364.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"1462_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2025.100362","volume":"5","author":"W Ali","year":"2025","unstructured":"Ali W, Williams J, Xiong B, Zou J, Daneshjou R. Machine learning for early detection of hidradenitis suppurativa: a feasibility study using medical insurance claims data. JID Innov. 2025;5(3): 100362.","journal-title":"JID Innov"},{"issue":"1","key":"1462_CR107","first-page":"43","volume":"159","author":"S Crovella","year":"2024","unstructured":"Crovella S, Suleman M, Tricarico PM, et al. Harnessing artificial intelligence for advancing early diagnosis in hidradenitis suppurativa. Ital J Dermatol Venerol. 2024;159(1):43\u20139.","journal-title":"Ital J Dermatol Venerol"},{"key":"1462_CR108","doi-asserted-by":"publisher","first-page":"1200400","DOI":"10.3389\/fmedt.2024.1200400","volume":"6","author":"J Kirby","year":"2024","unstructured":"Kirby J, Kim K, Zivkovic M, et al. Uncovering the burden of hidradenitis suppurativa misdiagnosis and underdiagnosis: a machine learning approach. Front Med Technol. 2024;6:1200400.","journal-title":"Front Med Technol"},{"issue":"3","key":"1462_CR109","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/jdv.19639","volume":"38","author":"A Wiala","year":"2024","unstructured":"Wiala A, Ranjan R, Schnidar H, Rappersberger K, Posch C. Automated classification of hidradenitis suppurativa disease severity by convolutional neural network analyses using calibrated clinical images. J Eur Acad Dermatol Venereol. 2024;38(3):576\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1462_CR110","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13357","volume":"29","author":"I Hernandez Montilla","year":"2023","unstructured":"Hernandez Montilla I, Medela A, Mac Carthy T, et al. Automatic International Hidradenitis Suppurativa Severity Score System (AIHS4): a novel tool to assess the severity of hidradenitis suppurativa using artificial intelligence. Skin Res Technol. 2023;29(6): e13357.","journal-title":"Skin Res Technol"},{"key":"1462_CR111","doi-asserted-by":"crossref","unstructured":"Passera A, Muscianisi E, Demanse D, et al. New insights on hidradenitis suppurativa phenotypes and treatment response: an exploratory automated analysis of the SUNSHINE and SUNRISE trials. J Eur Acad Dermatol Venereol. 2024.","DOI":"10.1111\/jdv.20234"},{"issue":"1","key":"1462_CR112","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ad.2021.07.003","volume":"113","author":"A Martorell","year":"2022","unstructured":"Martorell A, Martin-Gorgojo A, Rios-Vinuela E, et al. Artificial intelligence in dermatology: a threat or an opportunity? Actas Dermosifiliogr. 2022;113(1):30\u201346.","journal-title":"Actas Dermosifiliogr"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01462-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01462-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01462-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:05:49Z","timestamp":1757207149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01462-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":112,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01462-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,29]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Falk G. Bechara received honoraria for participation in advisory boards, in clinical trials, and\/or as a speaker from AbbVie, Acelyrin, Boehringer Ingelheim, Celltrion, Dr. Wolff, Incyte Corporation, Inflarx, Janssen Cilag, Merck, M\u00f6lnlycke, MoonLake, Novartis, Sanofi, Sitala, and UCB. Angelo V. Marzano reports consultancy\/advisory board disease-relevant honoraria from AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, Incyte, Bristol Myers Squibb, and UCB. Antonio Martorell has received honoraria and\/or travel grants and\/or has acted as an advisory board member for Novartis, AbbVie, Janssen Cilag, UCB, Lilly, LEO Pharma, L\u2019Oreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squib, Sandoz, and Amgen. He has also worked as a principal investigator in clinical trials supported by AbbVie, UCB, Jansen, Bristol Myers Squibb, Lilly, Galderma, Sanofi, Moonlace, Incyte, and Novartis. Hessel H. van der Zee reports personal fees from AbbVie, InflaRx, Novartis, Galderma, and Incyte. Valeria Jordan M. is an employee and shareholder of Novartis. Nicolas Thomas is an employee and shareholder of Novartis. Ivette Alarcon is an employee and shareholder of Novartis. Axel P. Villani reports personal fees from Abbvie, personal fees from Almirall, personal fees from Amgen, personal fees from BMS, personal fees from Eli Lilly, personal fees from Janssen, personal fees from Leo pharma, personal fees from MSD, personal fees from Novartis, and personal fees from UCB during the conduct of the study. Christos C. Zouboulis has received advisory board and consultation fees from Almirall, Biogen, Boehringer-Ingelheim, CLS Behring, Eli Lilly and Company, Est\u00e9e Lauder, Idorsia, Incyte, Leo, L\u2019OREAL, MSD, NAOS-BIODERMA, Novartis, PPM, Sanofi, ShiRhom, Takeda, UCB, and ZuraBio and lecture honoraria from Almirall, Amgen, Biogen, BMS, NAOS-BIODERMA, L\u2019Or\u00e9al, Novartis, Pfizer, and UCB. His departments have received grants from Astra Zeneca, Boehringer-Ingelheim, BMS, Brandenburg Medical School Theodor Fontane, EADV, European Union, German Federal Ministry of Education and Research, GSK, Incyte, Inflarx, MSD, Novartis, Relaxera, Sanofi, and UCB for his participation as clinical and research investigator. He is president of the EHSF e.V., the Deutsches Register Morbus Adamantiades-Beh\u00e7et e.V., coordinator of the ALLOCATE Skin group of the European Reference Network for Rare and Complex Skin Diseases (ERN Skin), chair of the ARHS Task Force group of the EADV, and board member of the International Society for Beh\u00e7et\u2019s Disease. He is editor of the EADV News and co-copyright holder of IHS4 on behalf of the EHSF e.V. John R. Ingram is a consultant for AbbVie, Boehringer Ingelheim, Cantargia, ChemoCentryx, Citryll, Incyte, Insmed, Kymera Therapeutics, MoonLake, Novartis, UCB Pharma, UNION therapeutics, and Viela Bio. Until recently, he was the editor-in-chief of the British Journal of Dermatology and receives an authorship honorarium for two UpToDate HS chapters. He is the co-copyright holder of HiSQOL and the Investigator and Patient Global Assessment instruments for HS. His department receives income from the copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. The Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands and the Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany are healthcare providers of the European Reference Network for Rare and Complex Skin Diseases (ERN Skin).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}